Amedisys Inc logo

AMED - Amedisys Inc Share Price

$175.68 -0.4  -0.2%

Last Trade - 05/06/20

Large Cap
Market Cap £4.49bn
Enterprise Value £4.66bn
Revenue £1.56bn
Position in Universe 1045th / 6325
Unlock AMED Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Amedisys Inc revenues increased 5% to $491.7M. Net income increased 2% to $31.8M. Revenues reflect Hospice segment increase of 24% to $169.4M. Net income was partially offset by Home Health Care segment income decrease of 9% to $47.1M, Personal care segment income decrease of 20% to $1.2M. Basic Earnings per Share excluding Extraordinary Items remained flat at $0.98.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AMED Revenue Unlock AMED Revenue

Net Income

AMED Net Income Unlock AMED Revenue

Normalised EPS

AMED Normalised EPS Unlock AMED Revenue

PE Ratio Range

AMED PE Ratio Range Unlock AMED Revenue

Dividend Yield Range

AMED Dividend Yield Range Unlock AMED Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMED EPS Forecasts Unlock AMED Revenue
Profile Summary

Amedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. The Company owns and operates approximately 524 centers in 39 states and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness, such as heart disease, pulmonary disease, Alzheimer's and Human Immunodeficiency Virus (HIV)/Acquired Immuno Deficiency Syndrome (AIDS). The Personal care segment provides patients with assistance with the essential activities of daily living.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated June 28, 1994
Public Since August 17, 1994
No. of Shareholders: 495
No. of Employees: 21,300
Sector Healthcare
Industry Healthcare Providers & Services
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,379,165
Free Float (0.0%)
Eligible for
AMED Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AMED
Upcoming Events for AMED
Tuesday 9th June, 2020
Amedisys Inc Annual Shareholders Meeting
Wednesday 10th June, 2020
Amedisys Inc at William Blair Growth Stock Conference
Wednesday 29th July, 2020 Estimate
Q2 2020 Amedisys Inc Earnings Release
Tuesday 27th October, 2020 Estimate
Q3 2020 Amedisys Inc Earnings Release
Frequently Asked Questions for Amedisys Inc
What is the Amedisys Inc share price?

As of 05/06/20, shares in Amedisys Inc are trading at $175.68, giving the company a market capitalisation of £4.49bn. This share price information is delayed by 15 minutes.

How has the Amedisys Inc share price performed this year?

Shares in Amedisys Inc are currently trading at $175.68 and the price has moved by 55.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amedisys Inc price has moved by 43.11% over the past year.

What are the analyst and broker recommendations for Amedisys Inc?

Of the analysts with advisory recommendations for Amedisys Inc, there are there are currently 5 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Amedisys Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Amedisys Inc next release its financial results?

Amedisys Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Amedisys Inc dividend yield?

Amedisys Inc does not currently pay a dividend.

Does Amedisys Inc pay a dividend?

Amedisys Inc does not currently pay a dividend.

When does Amedisys Inc next pay dividends?

Amedisys Inc does not currently pay a dividend.

How do I buy Amedisys Inc shares?

To buy shares in Amedisys Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amedisys Inc?

Shares in Amedisys Inc are currently trading at $175.68, giving the company a market capitalisation of £4.49bn.

Where are Amedisys Inc shares listed? Where are Amedisys Inc shares listed?

Here are the trading details for Amedisys Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AMED
What kind of share is Amedisys Inc?

Based on an overall assessment of its quality, value and momentum, Amedisys Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amedisys Inc share price forecast 2020?

Shares in Amedisys Inc are currently priced at $175.68. At that level they are trading at 21.29% discount to the analyst consensus target price of 0.00.

Analysts covering Amedisys Inc currently have a consensus Earnings Per Share (EPS) forecast of 4.528 for the next financial year.

How can I tell whether the Amedisys Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amedisys Inc. Over the past six months, the relative strength of its shares against the market has been 6.09%. At the current price of $175.68, shares in Amedisys Inc are trading at 7.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amedisys Inc PE Ratio?

The Amedisys Inc PE ratio based on its reported earnings over the past 12 months is 42.44. The shares are currently trading at $175.68.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Amedisys Inc?

Amedisys Inc's management team is headed by:

Paul Kusserow - CHM
Scott Ginn - CFO
Michael North - CIO
Christopher Gerard - COO
Sharon Brunecz - CHO
David Kemmerly - OTH
Julie Klapstein - IND
Richard Lechleiter - LED
Vickie Capps - IND
Molly Coye - IND
Teresa Kline - IND
Denise Bohnert - CCO
Who are the major shareholders of Amedisys Inc?

Here are the top five shareholders of Amedisys Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 10.42% (3.38m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.83% (3.18m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 4.86% (1.57m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 4.8% (1.55m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 3.14% (1.02m shares)
Similar to AMED
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.